Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
None reported
|
| gptkbp:awards |
Various industry awards
|
| gptkbp:businessModel |
Biopharmaceutical development
Active in seeking partnerships |
| gptkbp:CEO |
Dr._Y._Paul_Wang
|
| gptkbp:clinicalTrials |
Improved patient outcomes
Phase 1, Phase 2, Phase 3 Published in peer-reviewed journals Ongoing clinical trials Phase 2 trials Positive preliminary results Multiple_sites_across_the_US |
| gptkbp:collaborations |
Academic institutions
|
| gptkbp:communityEngagement |
Active in local community initiatives
|
| gptkbp:communityEvents |
Participation in industry conferences
|
| gptkbp:communityOutreach |
Engagement in local health fairs
|
| gptkbp:corporateSocialResponsibility |
Engagement in health initiatives
|
| gptkbp:customerFeedback |
Incorporates feedback into development.
|
| gptkbp:employees |
51-200
|
| gptkbp:financialPerformance |
Growing revenue
Strong IP portfolio |
| gptkbp:focus |
Immuno-oncology
|
| gptkbp:founded |
2012
|
| gptkbp:founder |
Dr._Y._Paul_Wang
|
| gptkbp:funding |
Series C funding
|
| gptkbp:futurePlans |
Expand into new markets
|
| gptkbp:hasPrograms |
Composed of industry experts
|
| gptkbp:hasResearchInterest |
Conducts extensive market analysis
|
| gptkbp:headquarters |
gptkb:San_Carlos,_California
|
| gptkbp:healthcare |
Involvement in patient advocacy groups
|
| https://www.w3.org/2000/01/rdf-schema#label |
Apexigen, Inc.
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:investmentFocus |
Various venture capital firms
Transparent communication with investors |
| gptkbp:leadership |
Experienced executives
|
| gptkbp:leads |
Top-tier venture capitalists
|
| gptkbp:market |
Global market
Scheduled for upcoming years |
| gptkbp:marketSegment |
Targeted therapies for cancer
|
| gptkbp:mission |
To develop innovative therapies for cancer treatment.
|
| gptkbp:partnerships |
Various pharmaceutical companies
Collaborations with research institutions |
| gptkbp:patentCitation |
Multiple patents in immunotherapy
|
| gptkbp:products |
APX005M
Focus on novel therapies |
| gptkbp:regulatoryCompliance |
Adheres to industry regulations
FDA_approval_process |
| gptkbp:research_areas |
Oncology
|
| gptkbp:researchAndDevelopment |
Significant investment
|
| gptkbp:researchFocus |
Monoclonal antibodies
|
| gptkbp:researchInterest |
Published research articles
|
| gptkbp:stockSymbol |
APGN
|
| gptkbp:strategicGoals |
Expand product pipeline
|
| gptkbp:subsidiary |
None known
|
| gptkbp:sustainabilityPractices |
Commitment to sustainable practices
|
| gptkbp:technology |
Focus on cutting-edge research
Proprietary technology |
| gptkbp:training |
Ongoing professional development programs
|
| gptkbp:tributaryOf |
Multiple drug candidates
|
| gptkbp:type |
Public Company
|
| gptkbp:website |
www.apexigen.com
|